Literature DB >> 21876069

Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms).

Paolo Mulatero1, Davide Tizzani, Andrea Viola, Chiara Bertello, Silvia Monticone, Giulio Mengozzi, Domenica Schiavone, Tracy Ann Williams, Silvia Einaudi, Antonio La Grotta, Franco Rabbia, Franco Veglio.   

Abstract

Primary aldosteronism (PA) is the most frequent cause of secondary hypertension, and patients display an increased prevalence of cardiovascular events compared with essential hypertensives. To date, 3 familial forms of PA have been described and termed familial hyperaldosteronism types I, II, and III (FH-I to -III). The aim of this study was to investigate the prevalence and clinical characteristics of the 3 forms of FH in a large population of PA patients. Three-hundred consecutive PA patients diagnosed in our unit were tested by long-PCR of the CYP11B1/CYP11B2 hybrid gene that causes FH-I, and all of the available relatives of PA patients were screened to confirm or exclude PA and, thus, FH-II. Urinary 18-hydroxycortisol and 18-oxocortisol were measured in all of the familial PA patients. Two patients were diagnosed with FH-I (prevalence: 0.66%), as well as 21 of their relatives, and clinical phenotypes of the 2 affected families varied markedly. After exclusion of families who refused testing and those who were not informative, 199 families were investigated, of which 12 were diagnosed with FH-II (6%) and an additional 15 individuals had confirmed PA; clinical and biochemical phenotypes of FH-II families were not significantly different from sporadic PA patients. None of the families displayed a phenotype compatible with FH-III diagnosis. Our study demonstrates that familial forms of hyperaldosteronism are more frequent than previously expected and reinforces the recommendation of the Endocrine Society Guidelines to screen all first-degree hypertensive relatives of PA patients.

Entities:  

Mesh:

Year:  2011        PMID: 21876069     DOI: 10.1161/HYPERTENSIONAHA.111.175083

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  32 in total

Review 1.  Primary aldosteronism in 2011: Towards a better understanding of causation and consequences.

Authors:  Michael Stowasser
Journal:  Nat Rev Endocrinol       Date:  2011-12-13       Impact factor: 43.330

Review 2.  Familial hyperaldosteronism type III a novel case and review of literature.

Authors:  Natividad Pons Fernández; Francisca Moreno; Julia Morata; Ana Moriano; Sara León; Carmen De Mingo; Ángel Zuñiga; Fernando Calvo
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

Review 3.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

Review 4.  Hyperaldosteronism: How to Discriminate Among Different Disease Forms?

Authors:  Valentina Crudo; Silvia Monticone; Jacopo Burrello; Fabrizio Buffolo; Martina Tetti; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-02

Review 5.  Leveraging melanocortin pathways to treat glomerular diseases.

Authors:  Rujun Gong
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

6.  ARMC5 is not implicated in familial hyperaldosteronism type II (FH-II).

Authors:  S M C De Sousa; M Stowasser; J Feng; A W Schreiber; P Wang; C N Hahn; R D Gordon; D J Torpy; H S Scott; L Gagliardi
Journal:  J Hum Hypertens       Date:  2017-10-12       Impact factor: 3.012

7.  A marked proportional rise in IVC aldosterone following cosyntropin administration during AVS is a signal to the presence of adrenal hyperplasia in primary aldosteronism.

Authors:  G A Kline; J L Pasieka; A Harvey; B So; V C Dias
Journal:  J Hum Hypertens       Date:  2013-11-28       Impact factor: 3.012

Review 8.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

Review 9.  Multiplicity of hormone-secreting tumors: common themes about cause, expression, and management.

Authors:  Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2013-06-14       Impact factor: 5.958

10.  Functional characterization of two novel germline mutations of the KCNJ5 gene in hypertensive patients without primary aldosteronism but with ACTH-dependent aldosterone hypersecretion.

Authors:  Amalia Sertedaki; Athina Markou; Dimitrios Vlachakis; Sophia Kossida; Emilie Campanac; Dax A Hoffman; Maria De La Luz Sierra; Paraskevi Xekouki; Constantine A Stratakis; Gregory Kaltsas; George P Piaditis; George P Chrousos; Evangelia Charmandari
Journal:  Clin Endocrinol (Oxf)       Date:  2016-07-12       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.